OncoMatch/Clinical Trials/NCT06177925
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Is NCT06177925 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Carboplatin/Cisplatin for respiratory tract neoplasms.
Treatment: Adebrelimab · Carboplatin/Cisplatin · Etoposide — This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV (VALG)
Metastatic disease required
ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)，the number of metastatic lesions ≤ 5, the number of metastatic organs ≤ 3
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
no previous systemic chemotherapy
Cannot have received: radiotherapy
no previous...radiotherapy
Cannot have received: immune checkpoint inhibitor
no previous...immune checkpoint inhibitor treatment
Cannot have received: immune checkpoint blockade therapies
Prior treatment with immune checkpoint blockade therapies
Cannot have received: allogeneic bone marrow transplantation
Prior allogeneic bone marrow transplantation
Cannot have received: solid organ transplant
solid organ transplant
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate end organ function
Liver function
Adequate end organ function
Adequate hematologic and end organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify